# Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics

**Authors:** Deepanjan Datta, Viola Colaco, Maria Nison, Ananya Prabha H, Sony Priyanka Bandi, Namdev Dhas, Vasudev R Pai, Praveen Halagali, Vamshi Krishna Tippavajhala, Sudarshan Singh, Lalitkumar K. Vora

PMC · DOI: 10.1039/d5ra09767c · RSC Advances · 2026-03-18

## TL;DR

Smart microdevices that respond to internal body signals can improve drug delivery by releasing medicine only where and when it's needed, reducing side effects and increasing effectiveness.

## Contribution

This review introduces smart microdevices that use endogenous stimuli for precise, real-time drug delivery, offering safer and more effective therapeutic solutions.

## Key findings

- Endogenous stimuli like pH, temperature, and enzymatic activity can trigger drug release in smart microdevices.
- Microfabrication and nanomaterials enable the development of sensitive and selective drug delivery systems.
- Future trends include AI feedback loops and wearable biosensors for personalized medicine.

## Abstract

The landscape of drug delivery has undergone a transformative shift with the emergence of adaptive therapeutics, smart microdevices engineered to respond dynamically to specific physiological or externally applied stimuli. These stimuli-responsive systems represent a significant advancement over conventional delivery methods by offering precise spatiotemporal control over drug release, thereby enhancing therapeutic efficacy and minimizing off-target effects and systemic toxicity. This review delves into the foundational design principles and material innovations that underpin these responsive microdevices. It highlights the role of endogenous stimuli such as pH gradients, temperature fluctuations, enzymatic activity, and redox, ionic, and hypoxia-responsive elements in activating drug release mechanisms. The integration of cutting-edge microfabrication techniques, nanomaterials, and bioinspired architectures has enabled the development of devices that are not only highly sensitive and selective but also capable of navigating complex biological environments. Furthermore, the article explores and examines the challenges associated with scalability, long-term biocompatibility, biosafety, and toxicity of implanted microdevices. Emerging trends such as AI-enhanced feedback loops, wearable biosensors, and closed-loop delivery platforms are discussed as future directions that could redefine personalized medicine. By bridging engineering ingenuity with biomedical imperatives, stimuli-responsive microdevices are poised to revolutionize drug delivery, offering intelligent, patient-centric solutions that adapt in real time to the dynamic needs of the human body. Notably, stimulus-responsive microdevices may soon facilitate localized delivery of imaging contrast agents, pharmaceuticals, genes, and mRNA; enable minimally invasive surgical procedures; and assist in cellular micromanipulation.

The drug delivery landscape has advanced with the emergence of adaptive therapeutics, comprising smart microdevices engineered for controlled, endogenous stimulus‑responsive drug delivery.

## Full-text entities

- **Diseases:** toxicity (MESH:D064420), hypoxia (MESH:D000860)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12997546/full.md

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12997546/full.md

## References

422 references — full list in the complete paper: https://tomesphere.com/paper/PMC12997546/full.md

---
Source: https://tomesphere.com/paper/PMC12997546